Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes

  1. Angela Kim
  2. Jakob G Knudsen
  3. Joseph C Madara
  4. Anna Benrick
  5. Thomas Hill
  6. Lina Abdul-Kadir
  7. Joely A Kellard
  8. Lisa Mellander
  9. Caroline Miranda
  10. Haopeng Lin
  11. Timothy James
  12. Kinga Suba
  13. Aliya F Spigelman
  14. Yanling Wu
  15. Patrick E Macdonald
  16. Ingrid Wernstedt Asterholm
  17. Tore Magnussen
  18. Mikkel Christensen
  19. Tina Visboll
  20. Victoria Salem
  21. Filip K Knop
  22. Patrik Rorsman
  23. Bradford B Lowell
  24. Linford JB Briant  Is a corresponding author
  1. Beth Israel Deaconess Medical Center, United States
  2. University of Copenhagen, Denmark
  3. University of Gothenburg, Sweden
  4. University of Oxford, United Kingdom
  5. University of Alberta, Canada
  6. Oxford University Hospitals, United Kingdom
  7. Imperial College London, United Kingdom

Abstract

Insulin-induced hypoglycemia is a major barrier to the treatment of type-1 diabetes (T1D). Accordingly, it is important that we understand the mechanisms regulating the circulating levels of glucagon - the body's principal blood glucose-elevating hormone which is secreted from alpha-cells of the pancreatic islets. Varying glucose over the range of concentrations that occur physiologically between the fed and fuel-deprived states (from 8 to 4 mM) has no significant effect on glucagon secretion in the perfused mouse pancreas or in isolated mouse islets (in vitro) and yet associates with dramatic changes in plasma glucagon in vivo. The identity of the systemic factor(s) that stimulates glucagon secretion remains unknown. Here, we show that arginine-vasopressin (AVP), secreted from the posterior pituitary, stimulates glucagon secretion. Glucagon-secreting alpha-cells express high levels of the vasopressin 1b receptor gene (Avpr1b). Activation of AVP neurons in vivo increased circulating copeptin (the C-terminal segment of the AVP precursor peptide, a stable surrogate marker of AVP) and increased blood glucose; effects blocked by pharmacological antagonism of either the glucagon receptor or vasopressin 1b receptor. AVP also mediates the stimulatory effects of hypoglycemia produced by exogenous insulin and 2-deoxy-D-glucose on glucagon secretion. We show that the A1/C1 neurons of the medulla oblongata drive AVP neuron activation in response to insulin-induced hypoglycemia. Exogenous injection of AVP in vivo increased cytoplasmic Ca2+ in alpha-cells (implanted into the anterior chamber of the eye) and glucagon release. Hypoglycemia also increases circulating levels of AVP in humans and this hormone stimulates glucagon secretion from isolated human islets. In patients with T1D, hypoglycemia failed to increase both plasma copeptin and glucagon levels. These findings suggest that AVP is a physiological systemic regulator of glucagon secretion and that this mechanism becomes impaired in T1D.

Data availability

The study data are available as a supplementary file.

Article and author information

Author details

  1. Angela Kim

    Medicine, Beth Israel Deaconess Medical Center, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9475-0798
  2. Jakob G Knudsen

    University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  3. Joseph C Madara

    Department of Medicine, Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Anna Benrick

    University of Gothenburg, Gothenburg, Sweden
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4616-6789
  5. Thomas Hill

    University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Lina Abdul-Kadir

    University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Joely A Kellard

    University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0822-1460
  8. Lisa Mellander

    University of Gothenburg, Gothenburg, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  9. Caroline Miranda

    University of Gothenburg, Gotheburg, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  10. Haopeng Lin

    University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  11. Timothy James

    Clinical Biochemstry, Oxford University Hospitals, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Kinga Suba

    Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Aliya F Spigelman

    University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  14. Yanling Wu

    University of Gothenburg, Gothenburg, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  15. Patrick E Macdonald

    University of Alberta, Edmonton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  16. Ingrid Wernstedt Asterholm

    University of Gothenburg, Gothenburg, Sweden
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0755-5784
  17. Tore Magnussen

    University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  18. Mikkel Christensen

    University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  19. Tina Visboll

    University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  20. Victoria Salem

    Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  21. Filip K Knop

    University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  22. Patrik Rorsman

    University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7578-0767
  23. Bradford B Lowell

    Department of Medicine, Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0436-3760
  24. Linford JB Briant

    University of Oxford, Oxford, United Kingdom
    For correspondence
    linford.briant@ocdem.ox.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3619-3177

Funding

Wellcome Trust (201325/Z/16/Z)

  • Linford JB Briant

National Institutes of Health (F31 DK109575)

  • Angela Kim

Diabetes UK ((Harry Keen Clinical Fellowship))

  • Victoria Salem

Diabetesförbundet

  • Patrik Rorsman

H2020 European Research Council (322620)

  • Patrik Rorsman

Leona M. and Harry B. Helmsley Charitable Trust

  • Patrik Rorsman
  • Linford JB Briant

Vetenskapsrådet ((Swedish Research Council))

  • Ingrid Wernstedt Asterholm
  • Patrik Rorsman

Wellcome Trust (095531)

  • Patrik Rorsman

Wellcome Trust (884655)

  • Patrik Rorsman

Canadian Institutes of Health Research (148451)

  • Patrick E Macdonald

Knut och Alice Wallenbergs Stiftelse

  • Patrik Rorsman

National Institutes of Health (R01 DK075632,R01 DK089044,R01 DK111401,R01 DK096010,P30 DK046200,P30 DK057521)

  • Bradford B Lowell

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were conducted in strict accordance to regulations enforced by the research institution. Experiments conducted in the UK were done so in accordance with the UK Animals Scientific Procedures Act (1986) (P0A6474AE, P0FA927F8) and University of Oxford and Imperial College London ethical guidelines, and were approved by the local Ethical Committee. All animal care and experimental procedures conducted in the U.S.A. were approved by the Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee. Animal experiments conducted in Goteborg University were approved by a local Ethics Committee.

Human subjects: Ethics statements are given in the Methods as follows:Clamping studies were conducted at Gentofte Hospital, University of Copenhagen. The studies were approved by the Scientific-Ethical Committee of the Capital Region of Denmark (registration no. H-D-2009-0078) and was conducted according to the principles of the Declaration of Helsinki (fifth revision, Edinburgh, 2000).Human pancreatic islets were isolated, with ethical approval and clinical consent, at the Diabetes Research and Wellness Foundation Human Islet Isolation Facility (OCDEM, Oxford, UK) or Alberta Diabetes Institute IsletCore (University of Alberta, AB, Canada).

Copyright

© 2021, Kim et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,152
    views
  • 347
    downloads
  • 26
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Angela Kim
  2. Jakob G Knudsen
  3. Joseph C Madara
  4. Anna Benrick
  5. Thomas Hill
  6. Lina Abdul-Kadir
  7. Joely A Kellard
  8. Lisa Mellander
  9. Caroline Miranda
  10. Haopeng Lin
  11. Timothy James
  12. Kinga Suba
  13. Aliya F Spigelman
  14. Yanling Wu
  15. Patrick E Macdonald
  16. Ingrid Wernstedt Asterholm
  17. Tore Magnussen
  18. Mikkel Christensen
  19. Tina Visboll
  20. Victoria Salem
  21. Filip K Knop
  22. Patrik Rorsman
  23. Bradford B Lowell
  24. Linford JB Briant
(2021)
Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes
eLife 10:e72919.
https://doi.org/10.7554/eLife.72919

Share this article

https://doi.org/10.7554/eLife.72919

Further reading

    1. Cancer Biology
    2. Cell Biology
    Kourosh Hayatigolkhatmi, Chiara Soriani ... Simona Rodighiero
    Tools and Resources

    Understanding the cell cycle at the single-cell level is crucial for cellular biology and cancer research. While current methods using fluorescent markers have improved the study of adherent cells, non-adherent cells remain challenging. In this study, we addressed this gap by combining a specialized surface to enhance cell attachment, the FUCCI(CA)2 sensor, an automated image analysis pipeline, and a custom machine learning algorithm. This approach enabled precise measurement of cell cycle phase durations in non-adherent cells. This method was validated in acute myeloid leukemia cell lines NB4 and Kasumi-1, which have unique cell cycle characteristics, and we tested the impact of cell cycle-modulating drugs on NB4 cells. Our cell cycle analysis system, which is also compatible with adherent cells, is fully automated and freely available, providing detailed insights from hundreds of cells under various conditions. This report presents a valuable tool for advancing cancer research and drug development by enabling comprehensive, automated cell cycle analysis in both adherent and non-adherent cells.

    1. Cell Biology
    Fatima Tleiss, Martina Montanari ... C Leopold Kurz
    Research Article

    Multiple gut antimicrobial mechanisms are coordinated in space and time to efficiently fight foodborne pathogens. In Drosophila melanogaster, production of reactive oxygen species (ROS) and antimicrobial peptides (AMPs) together with intestinal cell renewal play a key role in eliminating gut microbes. A complementary mechanism would be to isolate and treat pathogenic bacteria while allowing colonization by commensals. Using real-time imaging to follow the fate of ingested bacteria, we demonstrate that while commensal Lactiplantibacillus plantarum freely circulate within the intestinal lumen, pathogenic strains such as Erwinia carotovora or Bacillus thuringiensis, are blocked in the anterior midgut where they are rapidly eliminated by antimicrobial peptides. This sequestration of pathogenic bacteria in the anterior midgut requires the Duox enzyme in enterocytes, and both TrpA1 and Dh31 in enteroendocrine cells. Supplementing larval food with hCGRP, the human homolog of Dh31, is sufficient to block the bacteria, suggesting the existence of a conserved mechanism. While the immune deficiency (IMD) pathway is essential for eliminating the trapped bacteria, it is dispensable for the blockage. Genetic manipulations impairing bacterial compartmentalization result in abnormal colonization of posterior midgut regions by pathogenic bacteria. Despite a functional IMD pathway, this ectopic colonization leads to bacterial proliferation and larval death, demonstrating the critical role of bacteria anterior sequestration in larval defense. Our study reveals a temporal orchestration during which pathogenic bacteria, but not innocuous, are confined in the anterior part of the midgut in which they are eliminated in an IMD-pathway-dependent manner.